Multimodality therapy for stage III non-small-cell lung cancer.
about
Particle therapy versus conventional radiotherapy for lung cancerParticle therapy versus conventional radiotherapy for lung cancerSurgery for local and locally advanced non-small cell lung cancerTargeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma.The role of cytochrome c oxidase subunit Va in non-small cell lung carcinoma cells: association with migration, invasion and prediction of distant metastasis.Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancerQuality of care in non-small-cell lung cancer: findings from 11 oncology practices in FloridaPreclinical and pilot clinical studies of docetaxel chemoradiation for Stage III non-small-cell lung cancerExperimental computed tomography-guided vena cava puncture in pigs for percutaneous brachytherapy of middle mediastinal lymph node metastases.Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancerDEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer.Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment.What is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941?Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review.Low energy proton beam induces efficient cell killing in A549 lung adenocarcinoma cells.Microscopic N2 disease exhibits a better prognosis in resected non-small-cell lung cancer.A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response.Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.Evaluation of Failure Patterns Using Trimodality in Non-Small Cell Lung Cancer.Cisplatin-controlled p53 gene therapy for human non-small cell lung cancer xenografts in athymic nude mice via the CArG elements.Correlation between [¹⁸F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer.Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer.Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy.[Prevention of refractory cough with mediastinal fat to fill the residual cavity after radical systematic mediastinal lymphadenectomy in patients with right lung cancer].Role of surgery for stage IIIA-N2 non-small cell lung cancer.125 Iodine brachytherapy via a trans-superior vena cava approach in patients with metastases in middle mediastinal lymph nodes: a novel approach.Reirradiation for locoregionally recurrent non-small cell lung cancer
P2860
Q24187710-6B732376-FDCE-4983-9C17-0EEB39C7427DQ24241421-4DE6228D-7365-4EDB-AB7D-0BBEE35EC092Q24245182-BE07731B-B174-47D1-B9D3-22DAD0F976AFQ33699499-16E87F05-D753-45C4-AC81-90E5A741E29EQ34322658-B5F8F487-73F2-4CCA-872A-80FB1C0B6DF0Q35532111-1F327A33-2C67-40EB-8664-208E2E39194EQ35540726-AF219EE5-CD46-4C10-996D-C5A41DC87957Q35559805-2653F21C-4F21-41E7-905F-207064610919Q35706951-EE0D30E6-424A-473B-9A95-0115BDEFAF3CQ36801445-2B1A8B89-41BD-4F92-9997-41E8D138BBE4Q36852163-0DEB6B76-888A-4576-8752-0CC49AF4CC17Q36999751-B7CCD188-BEBF-4AB4-BE25-242B726682A9Q37042501-DA833211-95EF-4CAD-9870-C6692F4DCAF2Q37085999-F60FE721-E3E5-46FC-8464-E7D3C59D72D4Q37672787-B926EEFD-C671-4109-82A2-5594EC8264C0Q39731118-DFFBD3C1-482D-4D13-8C18-568DD9DB4165Q39964574-E1C7B04D-F338-4653-911E-FC9C2ABC01D3Q40016488-B1ED9E12-A6C0-4CCC-9287-B5B3B376DC39Q43379649-7A456D4E-9276-4265-9A1F-D0059417D33AQ44523924-748C53C4-7FE6-4361-9235-B584FCB5741AQ45887757-FC645A73-7A1E-42DA-9B92-F07780BCE0ABQ46730564-9367EBEF-4E38-4A30-8376-7D5E1F5AAE00Q49256406-6FCC80A3-1F32-4C0B-A77F-13737EFAD5ACQ53125167-DEF82334-694A-4949-A5F4-B81C23128DCBQ53294703-3CE2B308-68DF-486F-945F-365D489BD5AEQ53741620-8586DD5D-49B5-4D8B-83B3-5E21BC356660Q54752158-6EB58026-F7C7-4A25-B3BC-8A2D0024A7A0Q58804832-494712BF-3FA8-473F-B06F-877ADEA9839B
P2860
Multimodality therapy for stage III non-small-cell lung cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Multimodality therapy for stage III non-small-cell lung cancer.
@ast
Multimodality therapy for stage III non-small-cell lung cancer.
@en
type
label
Multimodality therapy for stage III non-small-cell lung cancer.
@ast
Multimodality therapy for stage III non-small-cell lung cancer.
@en
prefLabel
Multimodality therapy for stage III non-small-cell lung cancer.
@ast
Multimodality therapy for stage III non-small-cell lung cancer.
@en
P2093
P356
P1476
Multimodality therapy for stage III non-small-cell lung cancer.
@en
P2093
Daniel Farray
Kathy S Albain
Nena Mirkovic
P304
P356
10.1200/JCO.2005.03.008
P407
P577
2005-05-01T00:00:00Z